- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06424041
Fecal Microbiome Transplantation From Healthy Donors to Individuals With Fibromyalgia (FM-FMT-RCT)
Fecal Microbiome Transplantation From Healthy Donors to Individuals With Fibromyalgia: A Prospective Randomized, Controlled Double-Blind Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A double-blind, randomized placebo-controlled study to test the therapeutic potential of encapsulated oral fecal microbiota transplantation (FMT) from healthy donors to humans with fibromyalgia.
Fibromyalgia, a chronic and debilitating syndrome characterized by widespread pain, fatigue, sleep disturbances, and cognitive dysfunction poses a significant clinical, social, and economic burden globally, with limited targeted treatment options available. Recent studies have shed light on the potential role of the gut microbiome in fibromyalgia pathogenesis, highlighting alterations in gut microbiome composition correlated with clinical indices of the syndrome. Building upon this knowledge, the study seeks to explore the therapeutic potential of FMT, a well-established treatment increasingly investigated across various medical conditions. Preclinical investigations in mice have shown that FMT from fibromyalgia patients induces symptoms of the syndrome, while FMT from healthy controls reverses them. Encouragingly, preliminary results from an open-label pilot clinical trial involving fibromyalgia patients receiving encapsulated oral FMT from healthy donors demonstrated significant improvements in pain intensity, symptomatic burden, and quality of life measures, with favorable safety profiles. Based on these promising findings, a prospective randomized, controlled double-blind study is proposed to further evaluate the efficacy and safety of encapsulated oral FMT from healthy individuals in fibromyalgia patients. Clinical outcomes, as well as stool and serum samples, will be extensively characterized to elucidate the mechanisms underlying the effects of FMT, including its modulation of gut microbiome composition and function. The hypotheses involve expecting clinically significant improvements in pain and other symptoms of fibromyalgia following FMT, alongside corresponding alterations in gut microbiome composition and metabolomics profiles. This study aims to contribute valuable insights into the potential role of FMT as a novel therapeutic approach for fibromyalgia, addressing an unmet need in the management of this challenging condition.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North
-
Haifa, North, Israel, 3109601
- Rambam Health Care Campus
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult women aged 18-75 years.
- Diagnosis of fibromyalgia confirmed according to the 2016 diagnostic criteria by a pain physician who is a part of the study team.
- An average reported pain of 6 or above during the preceding week.
- Has remained symptomatic despite receiving standard care for fibromyalgia.
Exclusion Criteria:
- Any active inflammatory condition (rheumatic, gastrointestinal or other).
- Malignant neoplasm in the preceding 5 years.
- Immunosuppression due to medical condition or treatment.
- Uncontrolled psychiatric pathology.
- Any other clinically important condition at the discretion of the investigator.
- Known allergy to the antibiotics or laxatives used in the preparation protocol, or severe food allergy.
- Active infection or expected antibiotic treatment in the upcoming 3 months after inclusion.
- Pregnancy or intention to conceive.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active Treatment - FMT
Participants in this arm will receive a total of 5 real FMT treatments administered weekly, followed by an additional 5 maintenance FMT treatments on a monthly basis.
The first induction treatment will consist of 30 grams, with subsequent treatments comprising 15 grams each.
|
Healthy donor fecal microbiome transplantation, following depletion of the endogenous microbial communities using antibiotics and bowel cleansing
|
Sham Comparator: Sham Treatment - FMT
Participants in this arm will receive a total of 5 sham FMT treatments administered weekly, followed by an additional 5 maintenance sham FMT treatments on a monthly basis.
The first induction treatment will consist of 30 grams, with subsequent treatments comprising 15 grams each.
|
Capsules containing preservative solution only, following depletion of the endogenous microbial communities using antibiotics and bowel cleansing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain intensity at week five post-transplantation
Time Frame: Week five post transplantation induction
|
Pain intensity will be assessed using the Visual Analogue Scale (VAS), with a score of zero indicating no pain and a score of 10 representing the worst possible pain.
|
Week five post transplantation induction
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall symptomatic burden
Time Frame: Week five post transplantation induction and then on months 1, 3, 6 after last FMT
|
As measured using the Fibromyalgia Impact Questionnaire (range 0-100, higher scores indicate worse symptoms)
|
Week five post transplantation induction and then on months 1, 3, 6 after last FMT
|
Anxiety and depression
Time Frame: Week five post transplantation induction and then on months 1, 3, 6 after last FMT
|
As assessed by the Hospital Anxiety and Depression Scale questionnaire (range 0-21 for each of the domains, higher scores indicate worse symptoms)
|
Week five post transplantation induction and then on months 1, 3, 6 after last FMT
|
Sleep quality
Time Frame: Week five post transplantation induction and then on months 1, 3, 6 after last FMT
|
As assessed by the Pittsburgh Sleep Quality Inventory (range 0-21, higher scores indicate worse sleep quality).
|
Week five post transplantation induction and then on months 1, 3, 6 after last FMT
|
Quantitative Sensory Testing
Time Frame: Week five post transplantation induction and then on months 1, 3, 6 after last FMT
|
Pressure, heat and cold pain thresholds (Kg/cm^2, degrees C respectively, lower thresholds indicate increased pain sensitivity)
|
Week five post transplantation induction and then on months 1, 3, 6 after last FMT
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Amir Minerbi, MD-PhD, Rambam Health Care Campus
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0521-23
- Weston Family Foundation (Other Grant/Funding Number: Weston Family Foundation)
- Israel Science Foundation (Other Grant/Funding Number: Israel Science Foundation)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromyalgia
-
University of AberdeenCompletedFibromyalgia | Fibromyalgia, Primary | Fibromyalgia, SecondaryUnited Kingdom
-
Eli Lilly and CompanyCompletedFibromyalgia, Primary | Fibromyalgia, SecondaryMexico
-
Rasmia ElgoharyNot yet recruiting
-
Tel-Aviv Sourasky Medical CenterCompletedFibromyalgia (FM)Israel
-
Yousra Hisham Abdel FattahCompletedFibromyalgia, PrimaryEgypt
-
Forest LaboratoriesCypress Bioscience, Inc.TerminatedPrimary FibromyalgiaUnited States
-
Universidade Federal do Rio Grande do NorteCompleted
-
Tonix Pharmaceuticals, Inc.CompletedPrimary FibromyalgiaUnited States
-
Tonix Pharmaceuticals, Inc.CompletedPrimary FibromyalgiaUnited States
-
University of ManitobaCompleted
Clinical Trials on Fecal Microbiome Transplantation
-
Yonsei UniversityRecruitingInflammatory Bowel DiseasesKorea, Republic of
-
Professor Klaus BønnelykkeNot yet recruitingMicrobial ColonizationDenmark
-
Medical University of GrazUniversity of RostockCompletedCongenital Diaphragmatic HerniaAustria
-
Hvidovre University HospitalOdense University Hospital; University of Copenhagen; Psychiatric Center BallerupRecruitingAnorexia Nervosa | Microbiome DysbiosisDenmark
-
Leiden University Medical CenterDutch Donor Feces Bank; Vedanta BiosciencesUnknown
-
Tel-Aviv Sourasky Medical CenterWeizmann Institute of ScienceRecruitingAtopic DermatitisIsrael
-
Children's Mercy Hospital Kansas CityUniversity of Pittsburgh; Stanford UniversityCompletedUlcerative Colitis (UC) | Inflammatory Bowel Diseases (IBD) | Crohn's Disease (CD)United States
-
Shanghai General Hospital, Shanghai Jiao Tong University...CompletedHematopoietic and Lymphoid Cell NeoplasmChina
-
Istanbul Medipol University HospitalTepecik Training and Research Hospital; Bozyaka Training and Research Hospital and other collaboratorsRecruitingInflammatory Bowel Diseases | Colonoscopy | MicrobiotaTurkey
-
Madhusudan (Madhu) Grover, MBBSRecruiting